Cartesian Therapeutics (RNAC) Total Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Total Current Liabilities for 12 consecutive years, with $15.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 6.31% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $15.9 million (up 6.31% YoY), while the FY2025 annual figure was $14.9 million, down 34.99% from the prior year.
• Total Current Liabilities rose to $15.9 million in Q1 2026 per RNAC's latest filing, from $14.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $68.2 million in Q4 2023 and bottomed at $12.3 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $26.2 million across 5 years, with a median of $23.7 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 75.18% — and 2023, when it soared 172.0%.
• Cartesian Therapeutics' Total Current Liabilities stood at $25.1 million in 2022, then jumped by 172.0% to $68.2 million in 2023, then plunged by 66.32% to $23.0 million in 2024, then slumped by 34.99% to $14.9 million in 2025, then grew by 6.75% to $15.9 million in 2026.
• Business Quant data shows RNAC's Total Current Liabilities at $15.9 million in Q1 2026, $14.9 million in Q4 2025, and $13.8 million in Q3 2025.